Holen Sie sich die Stockscreener-App
76.42
4.01%
-3.205
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NFLX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$79.62
Offen:
$79.11
24-Stunden-Volumen:
49.96M
Relative Volume:
1.10
Marktkapitalisierung:
$323.08B
Einnahmen:
$45.27B
Nettoeinkommen (Verlust:
$10.98B
KGV:
30.24
EPS:
2.5272
Netto-Cashflow:
$9.46B
1W Leistung:
-5.49%
1M Leistung:
-14.52%
6M Leistung:
-37.62%
1J Leistung:
-25.60%
1-Tages-Spanne:
$75.23
$79.15
1-Wochen-Bereich:
$75.23
$84.66
52-Wochen-Spanne:
$75.23
$134.12
Netflix Inc Stock (NFLX) Company Profile
Firmenname
Netflix Inc
Sektor
Branche
Telefon
408-540-3700
Adresse
121 ALBRIGHT WAY, LOS GATOS
Compare NFLX vs DIS, WBD, LYV, FOXA
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NFLX
Netflix Inc
|
76.52 | 336.17B | 45.27B | 10.98B | 9.46B | 2.5272 |
|
DIS
Walt Disney Co
|
102.31 | 191.54B | 95.62B | 13.27B | 7.06B | 6.7872 |
|
WBD
Warner Bros Discovery Inc
|
28.05 | 69.40B | 37.87B | 356.00M | 4.13B | 0.1876 |
|
LYV
Live Nation Entertainment Inc
|
155.75 | 35.09B | 24.57B | 532.09M | 1.59B | 1.37 |
|
FOXA
Fox Corporation
|
56.56 | 26.00B | 16.47B | 2.07B | 2.67B | 4.4433 |
Netflix Inc Stock (NFLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-23 | Bestätigt | Robert W. Baird | Outperform |
| 2026-01-21 | Bestätigt | BMO Capital Markets | Outperform |
| 2026-01-21 | Bestätigt | Canaccord Genuity | Buy |
| 2026-01-21 | Bestätigt | Deutsche Bank | Hold |
| 2026-01-21 | Bestätigt | Goldman | Neutral |
| 2026-01-21 | Bestätigt | Guggenheim | Buy |
| 2026-01-21 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2026-01-21 | Bestätigt | Morgan Stanley | Overweight |
| 2026-01-21 | Bestätigt | Needham | Buy |
| 2026-01-21 | Bestätigt | Oppenheimer | Outperform |
| 2026-01-21 | Bestätigt | Piper Sandler | Overweight |
| 2026-01-21 | Bestätigt | Pivotal Research Group | Hold |
| 2026-01-21 | Bestätigt | Rosenblatt | Neutral |
| 2026-01-21 | Bestätigt | Rothschild & Co Redburn | Buy |
| 2026-01-21 | Bestätigt | TD Cowen | Buy |
| 2026-01-21 | Bestätigt | UBS | Buy |
| 2026-01-21 | Bestätigt | Wolfe Research | Outperform |
| 2026-01-12 | Eingeleitet | HSBC Securities | Buy |
| 2026-01-09 | Bestätigt | Goldman | Neutral |
| 2025-12-08 | Herabstufung | Pivotal Research Group | Buy → Hold |
| 2025-12-08 | Herabstufung | Rosenblatt | Buy → Neutral |
| 2025-11-18 | Bestätigt | Barclays | Equal Weight |
| 2025-10-31 | Herabstufung | Erste Group | Buy → Hold |
| 2025-10-07 | Hochstufung | Seaport Research Partners | Neutral → Buy |
| 2025-09-17 | Hochstufung | Loop Capital | Hold → Buy |
| 2025-07-10 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2025-07-07 | Herabstufung | Seaport Research Partners | Buy → Neutral |
| 2025-07-02 | Bestätigt | Canaccord Genuity | Buy |
| 2025-07-02 | Bestätigt | Goldman | Neutral |
| 2025-06-20 | Bestätigt | Pivotal Research Group | Buy |
| 2025-06-12 | Bestätigt | Oppenheimer | Outperform |
| 2025-06-03 | Bestätigt | Jefferies | Buy |
| 2025-05-30 | Bestätigt | BofA Securities | Buy |
| 2025-05-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-04-21 | Bestätigt | BMO Capital Markets | Outperform |
| 2025-04-21 | Bestätigt | Barclays | Equal Weight |
| 2025-04-21 | Bestätigt | Canaccord Genuity | Buy |
| 2025-04-21 | Bestätigt | Guggenheim | Buy |
| 2025-04-21 | Bestätigt | JP Morgan | Overweight |
| 2025-04-21 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2025-04-21 | Bestätigt | MoffettNathanson | Buy |
| 2025-04-21 | Bestätigt | Morgan Stanley | Overweight |
| 2025-04-21 | Bestätigt | Oppenheimer | Outperform |
| 2025-04-21 | Bestätigt | Piper Sandler | Overweight |
| 2025-04-21 | Bestätigt | Pivotal Research Group | Buy |
| 2025-04-21 | Bestätigt | Wells Fargo | Overweight |
| 2025-04-17 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-03-27 | Eingeleitet | FBN Securities | Outperform |
| 2025-03-17 | Hochstufung | MoffettNathanson | Neutral → Buy |
| 2025-01-24 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2025-01-23 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-01-22 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-01-22 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2025-01-22 | Bestätigt | Oppenheimer | Outperform |
| 2025-01-22 | Bestätigt | Pivotal Research Group | Buy |
| 2025-01-22 | Hochstufung | Rosenblatt | Neutral → Buy |
| 2025-01-22 | Hochstufung | The Benchmark Company | Sell → Hold |
| 2025-01-16 | Hochstufung | Seaport Research Partners | Neutral → Buy |
| 2025-01-15 | Bestätigt | BMO Capital Markets | Outperform |
| 2025-01-15 | Bestätigt | Oppenheimer | Outperform |
| 2025-01-08 | Bestätigt | Goldman | Neutral |
| 2025-01-06 | Bestätigt | Argus | Buy |
| 2025-01-03 | Bestätigt | The Benchmark Company | Sell |
| 2024-12-19 | Bestätigt | UBS | Buy |
| 2024-12-16 | Herabstufung | Loop Capital | Buy → Hold |
| 2024-12-16 | Bestätigt | Oppenheimer | Outperform |
| 2024-12-11 | Bestätigt | JP Morgan | Overweight |
| 2024-11-20 | Bestätigt | Pivotal Research Group | Buy |
| 2024-10-18 | Bestätigt | Needham | Buy |
| 2024-10-18 | Bestätigt | Oppenheimer | Outperform |
| 2024-10-18 | Bestätigt | Pivotal Research Group | Buy |
| 2024-10-16 | Bestätigt | Loop Capital | Buy |
| 2024-10-11 | Bestätigt | Guggenheim | Buy |
| 2024-10-10 | Bestätigt | Morgan Stanley | Overweight |
| 2024-10-10 | Bestätigt | Oppenheimer | Outperform |
| 2024-10-07 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2024-10-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-10-01 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2024-09-05 | Eingeleitet | China Renaissance | Hold |
| 2024-08-30 | Bestätigt | Pivotal Research Group | Buy |
| 2024-07-17 | Bestätigt | Guggenheim | Buy |
| 2024-07-16 | Bestätigt | The Benchmark Company | Sell |
| 2024-07-15 | Bestätigt | BofA Securities | Buy |
| 2024-07-12 | Bestätigt | JP Morgan | Overweight |
| 2024-07-10 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2024-07-09 | Bestätigt | TD Cowen | Buy |
| 2024-07-02 | Bestätigt | Argus | Buy |
| 2024-05-28 | Bestätigt | Evercore ISI | Outperform |
| 2024-04-19 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2024-04-19 | Hochstufung | Needham | Hold → Buy |
| 2024-04-19 | Bestätigt | Pivotal Research Group | Buy |
| 2024-04-15 | Bestätigt | Deutsche Bank | Hold |
| 2024-04-12 | Bestätigt | Morgan Stanley | Overweight |
| 2024-04-12 | Bestätigt | Piper Sandler | Neutral |
| 2024-04-05 | Bestätigt | Pivotal Research Group | Buy |
| 2024-03-25 | Bestätigt | Citigroup | Neutral |
| 2024-03-12 | Bestätigt | Jefferies | Buy |
| 2024-03-11 | Bestätigt | Oppenheimer | Outperform |
| 2024-01-30 | Herabstufung | Seaport Research Partners | Buy → Neutral |
| 2024-01-25 | Hochstufung | DZ Bank | Hold → Buy |
| 2024-01-24 | Bestätigt | BMO Capital Markets | Outperform |
| 2024-01-24 | Bestätigt | BofA Securities | Buy |
| 2024-01-24 | Bestätigt | Canaccord Genuity | Buy |
| 2024-01-24 | Bestätigt | Evercore ISI | Outperform |
| 2024-01-24 | Bestätigt | Goldman | Neutral |
| 2024-01-24 | Bestätigt | Guggenheim | Buy |
| 2024-01-24 | Bestätigt | JP Morgan | Overweight |
| 2024-01-24 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2024-01-24 | Hochstufung | Macquarie | Neutral → Outperform |
| 2024-01-24 | Bestätigt | Morgan Stanley | Overweight |
| 2024-01-24 | Bestätigt | Oppenheimer | Outperform |
| 2024-01-24 | Bestätigt | Piper Sandler | Neutral |
| 2024-01-24 | Bestätigt | Pivotal Research Group | Buy |
| 2024-01-24 | Bestätigt | Redburn Atlantic | Buy |
| 2024-01-24 | Bestätigt | Robert W. Baird | Outperform |
| 2024-01-24 | Bestätigt | TD Cowen | Outperform |
| 2024-01-24 | Bestätigt | UBS | Buy |
| 2024-01-24 | Bestätigt | Wells Fargo | Overweight |
| 2023-09-18 | Bestätigt | Evercore ISI | Outperform |
| 2023-08-25 | Hochstufung | Loop Capital | Hold → Buy |
| 2023-07-24 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-07-17 | Bestätigt | Deutsche Bank | Buy |
| 2023-07-13 | Bestätigt | JP Morgan | Overweight |
| 2023-07-12 | Bestätigt | UBS | Buy |
| 2023-07-05 | Hochstufung | Goldman | Sell → Neutral |
| 2023-06-29 | Bestätigt | Citigroup | Buy |
| 2023-06-28 | Bestätigt | Oppenheimer | Outperform |
| 2023-06-13 | Bestätigt | BofA Securities | Buy |
| 2023-06-13 | Bestätigt | Guggenheim | Buy |
| 2023-04-19 | Bestätigt | Deutsche Bank | Buy |
| 2023-04-19 | Bestätigt | JP Morgan | Overweight |
| 2023-04-19 | Bestätigt | Jefferies | Buy |
| 2023-04-19 | Bestätigt | Piper Sandler | Neutral |
| 2023-04-19 | Bestätigt | Pivotal Research Group | Buy |
| 2023-04-19 | Bestätigt | Rosenblatt | Neutral |
| 2023-04-19 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-11 | Fortgesetzt | Robert W. Baird | Neutral |
| 2023-01-23 | Bestätigt | Argus | Buy |
| 2023-01-20 | Bestätigt | Canaccord Genuity | Buy |
| 2023-01-20 | Bestätigt | Deutsche Bank | Buy |
| 2023-01-20 | Bestätigt | Evercore ISI | Outperform |
| 2023-01-20 | Bestätigt | Goldman | Sell |
| 2023-01-20 | Bestätigt | Guggenheim | Buy |
| 2023-01-20 | Bestätigt | Jefferies | Buy |
| 2023-01-20 | Bestätigt | MoffettNathanson | Market Perform |
| 2023-01-20 | Bestätigt | Oppenheimer | Outperform |
| 2023-01-20 | Bestätigt | Piper Sandler | Neutral |
| 2023-01-20 | Bestätigt | Pivotal Research Group | Buy |
| 2023-01-20 | Bestätigt | Robert W. Baird | Neutral |
| 2023-01-20 | Bestätigt | The Benchmark Company | Sell |
| 2023-01-20 | Bestätigt | Wedbush | Outperform |
| 2023-01-20 | Bestätigt | Wolfe Research | Outperform |
| 2023-01-12 | Hochstufung | Jefferies | Hold → Buy |
| 2023-01-04 | Eingeleitet | New Street | Neutral |
| 2022-12-29 | Hochstufung | CFRA | Sell → Buy |
| 2022-12-14 | Bestätigt | Jefferies | Hold |
| 2022-12-09 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-06-14 | Herabstufung | The Benchmark Company | Hold → Sell |
| 2022-06-10 | Herabstufung | Goldman | Neutral → Sell |
| 2022-05-16 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-04-21 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-04-21 | Herabstufung | Edward Jones | Buy → Hold |
| 2022-04-20 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-04-20 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-04-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-04-20 | Hochstufung | Needham | Underperform → Hold |
| 2022-04-20 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-04-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-04-20 | Herabstufung | Pivotal Research Group | Buy → Sell |
| 2022-04-20 | Herabstufung | Stifel | Buy → Hold |
| 2022-04-20 | Herabstufung | UBS | Buy → Neutral |
| 2022-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-19 | Eingeleitet | Rosenblatt | Neutral |
| 2022-03-09 | Hochstufung | Wedbush | Underperform → Neutral |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Edward Jones | Hold → Buy |
| 2022-01-24 | Herabstufung | Jefferies | Buy → Hold |
| 2022-01-21 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-01-21 | Bestätigt | BofA Securities | Buy |
| 2022-01-21 | Bestätigt | Canaccord Genuity | Buy |
| 2022-01-21 | Bestätigt | Cowen | Outperform |
| 2022-01-21 | Bestätigt | Deutsche Bank | Hold |
| 2022-01-21 | Bestätigt | Goldman | Neutral |
| 2022-01-21 | Bestätigt | Guggenheim | Buy |
| 2022-01-21 | Bestätigt | JP Morgan | Overweight |
| 2022-01-21 | Bestätigt | MoffettNathanson | Neutral |
| 2022-01-21 | Herabstufung | Monness Crespi & Hardt | Buy → Neutral |
| 2022-01-21 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-21 | Bestätigt | Oppenheimer | Outperform |
| 2022-01-21 | Bestätigt | Piper Sandler | Overweight |
| 2022-01-21 | Bestätigt | Pivotal Research Group | Buy |
| 2022-01-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-01-21 | Bestätigt | Stifel | Buy |
| 2022-01-21 | Hochstufung | The Benchmark Company | Sell → Hold |
| 2022-01-21 | Herabstufung | Truist | Buy → Hold |
| 2022-01-21 | Bestätigt | UBS | Buy |
| 2022-01-21 | Bestätigt | Wolfe Research | Outperform |
| 2021-12-15 | Bestätigt | The Benchmark Company | Sell |
| 2021-10-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-10-20 | Bestätigt | Monness Crespi & Hardt | Buy |
| 2021-09-29 | Bestätigt | The Benchmark Company | Sell |
| 2021-09-13 | Eingeleitet | Goldman | Neutral |
| 2021-09-08 | Bestätigt | JP Morgan | Overweight |
| 2021-09-07 | Bestätigt | Atlantic Equities | Overweight |
| 2021-07-21 | Bestätigt | Credit Suisse | Outperform |
| 2021-07-21 | Bestätigt | Deutsche Bank | Buy |
| 2021-07-21 | Bestätigt | JP Morgan | Overweight |
| 2021-07-21 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2021-07-21 | Bestätigt | Stifel | Buy |
| 2021-06-25 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-06-25 | Eingeleitet | Edward Jones | Hold |
| 2021-05-19 | Fortgesetzt | Jefferies | Buy |
| 2021-04-21 | Fortgesetzt | Oppenheimer | Outperform |
| 2021-04-21 | Bestätigt | Pivotal Research Group | Buy |
| 2021-04-21 | Hochstufung | Stifel | Hold → Buy |
| 2021-04-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2021-04-01 | Eingeleitet | Piper Sandler | Overweight |
| 2021-03-25 | Bestätigt | The Benchmark Company | Sell |
| 2021-03-23 | Hochstufung | Argus | Hold → Buy |
| 2021-01-21 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-01-20 | Bestätigt | Monness Crespi & Hardt | Buy |
| 2021-01-20 | Bestätigt | Pivotal Research Group | Buy |
| 2021-01-20 | Bestätigt | The Benchmark Company | Sell |
| 2021-01-20 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-20 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-21 | Bestätigt | BMO Capital Markets | Outperform |
| 2020-10-21 | Bestätigt | Bernstein | Outperform |
| 2020-10-21 | Bestätigt | Jefferies | Buy |
| 2020-10-21 | Bestätigt | Morgan Stanley | Overweight |
| 2020-10-21 | Bestätigt | Oppenheimer | Outperform |
| 2020-10-21 | Bestätigt | Piper Sandler | Overweight |
| 2020-10-21 | Bestätigt | Pivotal Research Group | Buy |
| 2020-10-21 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-10-21 | Bestätigt | The Benchmark Company | Sell |
| 2020-10-21 | Bestätigt | Wedbush | Underperform |
| 2020-10-21 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-10-16 | Bestätigt | Morgan Stanley | Overweight |
| 2020-10-15 | Bestätigt | Canaccord Genuity | Buy |
| 2020-10-14 | Bestätigt | Goldman | Buy |
| 2020-10-07 | Bestätigt | Pivotal Research Group | Buy |
| 2020-09-28 | Bestätigt | The Benchmark Company | Sell |
| 2020-09-15 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-09-09 | Fortgesetzt | Raymond James | Mkt Perform |
| 2020-09-04 | Bestätigt | The Benchmark Company | Sell |
| 2020-07-29 | Bestätigt | Loop Capital | Buy |
Alle ansehen
Netflix Inc Aktie (NFLX) Neueste Nachrichten
DOJ Ousts Antitrust Chief Gail Slater, Who Was Reviewing Netflix-Warner Bros. Merger - Yahoo! Finance Canada
Netflix Acquires Stephen Curry and Ben Proudfoot’s Sundance-Winning MLK Speechwriter Doc Short (Exclusive) - The Hollywood Reporter
Why Nvidia, Intel, Netflix, and Palantir stocks crash today: US stock market in deep red as Nasdaq sinks 1 - The Economic Times
Netflix Has Released 28 Seasons of Its Sales Growth Series. What Will Season 29 Look Like? - The Motley Fool
Netflix stock drops 5% as Warner deal pushback grows — what’s next for NFLX - Bez Kabli
Trump met with David Ellison days before saying he’s ‘not involved’ in Paramount’s Netflix battle - CNN
Jay Shetty Launches Perfect Strangers, Netflix Deal for Two TV Series - Variety
Netflix stock crashes to 52-week low amid Warner Bros. deal - Rolling Out
Could Netflix Stock Help You Become a Millionaire? - AOL.com
David A Hyman Takes Money Off The Table, Sells $464K In Netflix Stock - Benzinga
AMC Networks is "in conversations" with Netflix about a potential "Walking Dead" streaming renewal, CEO Kristin Dolan told Wall Street analysts. Read more below. - facebook.com
Ancora Could See Multiple Ways to Win in Warner Bros. Fight - Bloomberg.com
8 High-Yield Dividend Stocks to Buy and Hold for Reliable Passive Income - Investing.com
Netflix stock hits 52-week low at $79 amid challenging year By Investing.com - Investing.com South Africa
Netflix stock hits 52-week low at $79 amid challenging year - Investing.com
Netflix unveils the trailer for 'That Night' - About Netflix
Opinion: Big Warner Bros. shareholders are getting restless in this Paramount-Netflix bidding war - MarketWatch
Netflix, Inc. $NFLX Shares Bought by CIBC Capital Markets Europe S.A. - MarketBeat
What Is Happening With Netflix Stock? - Trefis
Turkish Nobel Novelist Orhan Pamuk Gets the Netflix Series He Wanted - The New York Times
Netflix Stock Dropped -30%, Here’s Why - Trefis
Paramount ratchets up competition for Warner Bros. but still falls short - Axios
AMC Networks Posts Mixed Q4 as ‘Walking Dead’ Streaming Sweepstakes Begin - IMDb
Activist investor ancora opposes Netflix-WARNER BROS deal backs Paramount bid - Virginia Business
Activist Ancora urges Warner board to reject Netflix, reconsider Paramount's bid - The Edge Malaysia
Insider Sell: Gregory Peters Sells 27,312 Shares of Netflix Inc (NFLX) - GuruFocus
Insider Selling: Netflix (NASDAQ:NFLX) CEO Sells 27,312 Shares of Stock - MarketBeat
‘The Walking Dead’ Streaming Renewal Talks Underway As Netflix Deal Nears End, AMC Networks CEO Kristin Dolan Says - IMDb
Netflix (NFLX) Options Show Mixed Sentiment Amid Stock Dip - GuruFocus
Warner Bros. Discovery board faces pressure as activist investor threatens to vote no on Netflix deal - Los Angeles Times
3 Reasons to Buy Netflix Stock Now - Yahoo Finance
Ancora threatens proxy fight over Warner Bros Discovery’s acquisition deal with Netflix - Yahoo! Finance Canada
Netflix appeals French Community's "disproportionate" production support rules in court - belganewsagency.eu
Activist investor Ancora publicly opposes the WBD-Netflix deal - Yahoo Finance
Netflix announces 10-for-1 stock split as company aims to make stock more accessible for employees - AOL.com
Activist Investor Pushes Warner to Walk Away From Netflix Deal - The Wall Street Journal
Activist investor takes aim at Warner Bros deal with Netflix - Financial Times
Activist investor threatens proxy fight over Warner Bros Discovery’s deal with Netflix - Proactive financial news
Warner Bros. Gets an Activist. Why It Doesn’t Like the Netflix Deal. - Barron's
Small Warner Bros. Discovery Shareholder Blasts ‘Flawed, Inferior’ Netflix Offer and Backs Paramount’s Hostile Bid — but Will It Matter? - Yahoo Finance UK
Activist Ancora Urges Warner Board to Reject Netflix Bid - Bloomberg.com
Activist Investor Slams WBD For Rushing Into “Flawed” Netflix Deal, Tells Board To Engage With Paramount As Temperature Rises - Yahoo! Finance Canada
Netflix stock ticks up before the bell as activist targets Warner deal; what to watch next - Bez Kabli
‘This is a Sledgehammer,’ Says Investor About Netflix Stock - TipRanks
Activist Investor Puts Heat on Warner Bros. Discovery to Reject Netflix Offer For “Inferior Value” - The Hollywood Reporter
Cleveland-based activist Ancora urges Warner board to reject Netflix bid - Crain's Cleveland Business
Is Netflix’s 10% Dip a Buying Opportunity or a Warning Sign? - Yahoo Finance
Activist Ancora fund moves to block Netflix takeover of Warner studios - Euronews.com
Netflix (NFLX) Plunged Due to Investors’ Concerns Over Acquisition Pricing - Yahoo Finance
German Voice Actors Boycott Netflix Over AI Training Clause in New Contracts - BABL AI
Warner Bros. Gets an Activist. What It Means for the Netflix Takeover Battle. - Barron's
Finanzdaten der Netflix Inc-Aktie (NFLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.48%
0.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):